Welcome to our dedicated page for Corbus Pharmaceu SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
Corbus Pharmaceuticals Holdings, Inc.'s Chief Medical Officer, Dominic Smethurst, reported equity awards received on January 14, 2026. He was granted 28,365 restricted stock units (RSUs) that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027, and a pro rata acceleration feature if his service is terminated by the company without cause after the first vesting date. He also received an annual stock option award for 85,095 shares at an exercise price of $8.26 per share, vesting 25% on January 14, 2027 and the remaining 75% in equal monthly installments over 36 months starting February 14, 2027. Following these transactions, he beneficially owned 99,172 shares of common stock, including 93,065 unvested RSUs subject to their existing vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Financial Officer, Sean F. Moran. On January 14, 2026, he received 28,082 restricted stock units (RSUs) that will settle in common stock. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a pro rata acceleration feature if the company terminates his service without cause after the first vesting date. Following this grant, he beneficially owns 101,395 shares of common stock, including 85,714 unvested RSUs.
On the same date, he was also granted stock options to purchase 84,247 shares of common stock at an exercise price of $8.26 per share, expiring January 14, 2036. Under the company’s 2024 Equity Compensation Plan, 25% of this option vests on January 14, 2027, with the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.
Corbus Pharmaceuticals Holdings, Inc. CEO Yuval Cohen reported new equity awards. On January 14, 2026, he received 50,000 restricted stock units that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027. Following this grant, he beneficially owned 188,187 common shares, including 173,561 unvested RSUs subject to their vesting schedules. He was also granted stock options for 150,000 shares at an exercise price of $8.26, expiring January 14, 2036, with 25% vesting on January 14, 2027 and the remaining 75% vesting in equal monthly installments over 36 months starting February 14, 2027.
Corbus Pharmaceuticals Holdings, Inc. reported an equity compensation grant to its Chief Operating Officer, Ian Hodgson. On January 14, 2026, he received 28,365 restricted stock units (RSUs), which will be settled in common shares. These RSUs vest 25% on each of the first four anniversaries beginning January 14, 2027, with a provision for partial accelerated vesting if his service is terminated by the company without cause after the first vesting date.
On the same date, he was also granted 85,095 stock options with a $8.26 exercise price under the 2024 Equity Compensation Plan. Twenty‑five percent of this option vests on January 14, 2027, and the remaining 75% vests in equal monthly installments over 36 months starting February 14, 2027. Following these grants, he beneficially owned 54,342 shares of common stock, which include 53,108 unvested RSUs subject to their respective vesting schedules, and 85,095 options.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported that Aberdeen Group plc and its U.S. affiliate abrdn Inc. have become significant shareholders. The filing shows that these related entities beneficially own a total of 1,321,750 shares of Corbus common stock, representing 7.53% of the outstanding shares as of the reported date. Both Aberdeen Group plc (United Kingdom) and abrdn Inc. (United States) report shared voting and dispositive power over all of these shares, with no sole voting or sole dispositive authority.
The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Corbus, consistent with an institutional investment position under Schedule 13G. The filing notes that abrdn Inc. holds more than 5% of this class of stock on behalf of its underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as an intermediate holding company.
Corbus Pharmaceuticals Holdings, Inc. filed a current report to let investors know that management has updated the company’s investor presentation. The revised presentation is being used to describe its business and is furnished as Exhibit 99.1 to the report. The company notes that this material is being provided under a Regulation FD disclosure item, meaning it is intended to share information broadly with the market. The investor presentation and related materials are furnished rather than filed, so they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.
Corbus Pharmaceuticals Holdings, Inc. announced that long-time board member Alan Holmer has decided to retire from its Board of Directors. He notified the company of his resignation on December 12, 2025, and his service will end effective December 31, 2025. The company states that his decision to step down is due to retirement and is not the result of any disagreement with management or with the company’s operations, policies, or practices. This indicates an orderly governance transition rather than a conflict-driven departure.
Corbus Pharmaceuticals Holdings, Inc. insiders affiliated with Cormorant Asset Management reported selling 30,029 shares of common stock on 12/11/2025. The sale was coded as a disposition and executed in a series of open-market transactions at a weighted average price of $11.456 per share, with individual trade prices ranging from $11.20 to $12.15.
Following this transaction, the reporting persons indirectly beneficially owned 2,344,971 Corbus Pharmaceuticals shares. The filing states that all shares sold were held by Cormorant Global Healthcare Master Fund, LP and that each reporting person disclaims beneficial ownership beyond its or her pecuniary interest.
Corbus Pharmaceuticals (CRBP) reported Q3 2025 results, highlighting higher R&D spending as clinical programs advanced. The company posted a net loss of $23.3 million versus $13.8 million a year ago, driven by R&D of $20.9 million (up 93%) as CRB-701 and CRB-601 trials expanded and CRB-913 progressed in Phase 1. G&A declined to $3.6 million from $4.7 million.
Liquidity remained solid. Cash, cash equivalents and investments were $104.0 million as of September 30, 2025. Management stated that these resources, together with $73.8 million in net proceeds from recent equity sales and the 2025 public offering, are expected to fund operations for at least twelve months after this report’s issuance. Net cash used in operations was $48.6 million for the nine months.
Subsequent to quarter-end, the company sold 232,279 shares via its Open Market Sale Agreement for net proceeds of $3.6 million and completed a public offering on November 3, 2025, raising gross proceeds of $75.0 million (net $70.2 million). Shares outstanding were 12,534,853 as of September 30, 2025.
Corbus Pharmaceuticals Holdings, Inc. filed a current report describing that it issued a press release on November 12, 2025 with financial information and operating metrics for its fiscal quarter ended September 30, 2025, along with a discussion of its business outlook. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The company notes that the information provided under Items 2.02 and 7.01, including Exhibit 99.1, is being furnished to the SEC and is not deemed filed for liability purposes under the Exchange Act or automatically incorporated into other securities filings, unless specifically referenced.